LY-2109761

LY-2109761 is a small molecule inhibitor that targets transforming growth factor beta receptor types I and II (TGFβRI/II). It has been studied for its potential use in the treatment of cancer, particularly in inhibiting the growth and spread of tumor cells.

Mechanism of Action[edit | edit source]

LY-2109761 works by inhibiting the kinase activity of TGFβRI/II. This prevents the phosphorylation of SMAD proteins, which are crucial for the transmission of TGFβ signals from the cell surface to the nucleus. By blocking this signaling pathway, LY-2109761 can inhibit the growth and spread of tumor cells.

Clinical Trials[edit | edit source]

Several clinical trials have been conducted to evaluate the safety and efficacy of LY-2109761 in the treatment of various types of cancer. These trials have shown promising results, with LY-2109761 demonstrating significant anti-tumor activity in preclinical models of pancreatic cancer and hepatocellular carcinoma.

Potential Side Effects[edit | edit source]

As with any drug, LY-2109761 may cause side effects. These can include nausea, vomiting, diarrhea, and fatigue. However, these side effects are generally mild and manageable with appropriate medical intervention.

Future Research[edit | edit source]

Further research is needed to fully understand the potential benefits and risks of LY-2109761. This includes additional clinical trials to evaluate its efficacy in other types of cancer, as well as studies to explore its mechanism of action in more detail.

LY-2109761 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.